Patients who have been diagnosed with<unk>  often have poor outcomes. The four year survival rate without remission for local<unk>  tumors is 65 percent, while the four year survival rate with metastatic<unk>  is only 15 percent. Patients who have metastatic<unk>  positive with PAX3-FOXO1 fusion often have a poorer outcome than patients positive with PAX7-FOXO1 fusion, with a four-year survival rate of 8 percent and 75 percent respectively. Other variables affect the four year survival rate, such as primary tumor site, size of primary tumor, amount of local invasion, number of distal lymph nodes spread to, and whether metastasis has occurred. Prognosis for patients who have primary tumor sites within the bones often have higher survival rates and respond well to treatment options. While patients who have primary tumor sites within the nasopharynx region with metastases to the breast have very poor outcomes. Patients who are fusion protein negative with low risk clinical features should be treated with reduced therapy, while patients who are fusion protein positive with low risk clinical features should be treated as an intermediate risk and have more intensive therapy regimens.
Alveolar rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Spindle cell rhabdomyosarcoma
Neurofibroma
Lipoblastoma
Enchondroma
Nesidioblastoma
Esthesioneuroblastoma